BioVie ($BIVI): New Biomarker Data at NIH Workshop Help Explain Who Benefits Most from Bezisterim in Long COVID
BioVie presented new biomarker findings from its Phase 2 ADDRESS-LC trial at the NIH’s RECOVER-TLC workshop, the initiative created to speed the development of Long COVID treatments. Analyzing 380 plasma biomarkers, BioVie identified two distinct patient groups with different responses to bezisterim. In highly inflamed patients, it showed a large effect on objective cognition (p=0.001). In a less-inflamed group, it was associated with improvements in fatigue and post-exertional malaise. Bezisterim also lowered neuropeptide Y, a biomarker elevated in ME/CFS and Gulf War Syndrome, by about 33%. BioVie says the findings provide a potential biological explanation for its earlier clinical results and could help target future trials to the patients most likely to benefit. More data will be presented this week at the Long COVID International Conference in Nice.
Full press release: redchip.news/3WWntIt
BioVie presented new biomarker findings from its Phase 2 ADDRESS-LC trial at the NIH’s RECOVER-TLC workshop, the initiative created to speed the development of Long COVID treatments. Analyzing 380 plasma biomarkers, BioVie identified two distinct patient groups with different responses to bezisterim. In highly inflamed patients, it showed a large effect on objective cognition (p=0.001). In a less-inflamed group, it was associated with improvements in fatigue and post-exertional malaise. Bezisterim also lowered neuropeptide Y, a biomarker elevated in ME/CFS and Gulf War Syndrome, by about 33%. BioVie says the findings provide a potential biological explanation for its earlier clinical results and could help target future trials to the patients most likely to benefit. More data will be presented this week at the Long COVID International Conference in Nice.
Full press release: redchip.news/3WWntIt
www.redchip.com BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim… New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes1 associated with different patient responses to bezisterim treatment. Patients with a... 
